Amtagvi: the first cell therapy for a solid tumor — and responses lasting years
Published · Researched 2026-09-22
What happened (dated facts)
On February 16, 2024, the U.S. FDA granted accelerated approval to Amtagvi (lifileucel), the first tumor-derived T-cell (TIL) therapy approved for any solid tumor — for adults with unresectable or metastatic melanoma previously treated with PD-1 blockade. In the pivotal C-144-01 trial, the objective response rate was 31.5% in the primary cohort, including complete responses, in patients who had run out of options. The final five-year analysis (Journal of Clinical Oncology, 2025) showed unprecedented durability: ~31% ORR, median duration of response of 36+ months, nearly a third of responders still responding at five years, and 20% five-year overall survival — with real-world data later showing a 44% response rate. The label carries a boxed warning for treatment-related mortality, prolonged cytopenia, severe infection, and cardiopulmonary/renal impairment.
Why it is genuinely positive
Cell therapy had cured blood cancers but never a solid tumor — until this. For melanoma patients who failed every standard treatment, a one-time infusion of their own re-armed immune cells produced responses lasting years, with some patients alive and responding at five years. It opens the door to TIL therapy across solid tumors.
Social pulse
Strong oncology-press circulation around the February 2024 FDA approval and five-year durability data. On Threads, targeted searches returned a post about CAR-T for autoimmune disease (a different therapy) — no direct posts about Amtagvi were captured. The social layer here is oncology media rather than viral patient posts.
Verified quotes
None captured.
Verification
- Tier: 2
- Primary source: FDA approval summary (PubMed 40699950, https://pubmed.ncbi.nlm.nih.gov/40699950/) — proves approval date (Feb 16, 2024), first tumor-derived T-cell therapy, ORR 31.5%, boxed warning; five-year JCO analysis and real-world 44% ORR via Iovance/GlobeNewswire (https://www.globenewswire.com/news-release/2026/02/05/3233518/0/en/Best-in-Class-Real-World-Data-Support-Early-Amtagvi-Treatment-in-Advanced-Melanoma.html), February 2026.
- Social sources: health-press layer + targeted Threads searches (direct story posts not captured — noted honestly). Proves: sustained coverage and community relevance via health media.
- Positivity check: approved first-in-class cell therapy with durable multi-year responses in treatment-refractory patients — genuine, with the boxed warning stated.
Key facts
| Fact | Value | Source | Date |
|---|---|---|---|
| FDA accelerated approval | February 16, 2024 (Amtagvi, lifileucel) | FDA approval summary / PubMed | 2024-02-16 |
| Status | First tumor-derived T-cell therapy approved for a solid tumor | FDA approval summary | 2024-02-16 |
| Pivotal ORR | 31.5% (3 CR, 20 PR of 73), patients post-PD-1 | FDA approval summary | 2024 |
| 5-year analysis | ~31% ORR, median DOR 36+ months, 20% 5-yr OS | JCO via GlobeNewswire | 2025/2026-02 |
| Real-world | 44% ORR (52% in earlier lines) | GlobeNewswire | 2026-02-05 |
| Safety | Boxed warning: treatment-related mortality, prolonged cytopenia, severe infection, cardiopulmonary/renal impairment | FDA label summary | 2024 |
UNVERIFIED points
- Social-layer posts about Amtagvi were not yet observed; tier cannot be finalized until they are.
Sources
- Primary source: FDA approval summary (PubMed 40699950 — retrieval date not recorded
- Primary source: FDA approval summary (PubMed 40699950, https://pubmed.ncbi.nlm.nih.gov/40699950/) — proves approval date (Feb 16, 2024),… — retrieval date not recorded